Investor contact

Logo WILEX AGHeidelberg Pharma Research is a wholly owned subsidiary of WILEX AG. WILEX AG is a biopharmaceutical company in Munich which has a ready for partnering portfolio of antibody-based diagnostic and therapeutic Phase III product candidates for the detection and targeted treatment of clear cell renal cell carcinoma.
Research and development focus on the operations of its subsidiary Heidelberg Pharma Research GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and provides preclinical drug discovery and development services.
WILEX is listed at the Frankfurt Stock Exchange (ISIN DE000A11QVV0).